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Abstract
Damage in genetic material is induced through the action of several drugs (directly or 
indirectly). Specially, antimicrobials from quinolone class (such as ciprofloxacin) induce 
DNA damage that promotes the formation of the RecA filament leading to auto-cleavage 
of LexA and allows the expression of SOS genes, including the error-prone polymerase 
(like umuC). The SOS pathway plays a critical role in the acquisition of mutations that 
lead to the emergence of antibiotic-resistant bacteria and the spread of virulence factors. 
This chapter provides a comprehensive review about the SOS response of Staphylococcus 
aureus and the modulatory effects of new compounds (natural or synthetics) on this path-
way. The effects of some SOS inhibitors are highlighted such as baicalein and aminocou-
marins. Compounds able to prevent SOS response are extremely important to develop 
new combinatory approaches to inhibit S. aureus mutagenesis. The study of new SOS 
inductors could reveal new insights into the pathways used by S. aureus to acquire drug 
resistance; examples of these compounds are the lysine-peptoid hybrid LP5, cyclic pep-
tide inhibitors, etc. These studies can impact the development of new drugs. In conclu-
sion, we hope to provide essential information about the effects of compounds on SOS 
response from S. aureus.
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1. Introduction
Drug resistance is a well-known problem involved in the treatment of bacterial infections and 
its incidence is escalating in an alarming rate [1–3]. As a result, microbial diseases are still 
among the most serious problems to public health system, especially in developing coun-
tries where infectious diseases still represent a major cause of human mortality. Especially 
alarming is the rapid global spread of multiresistant bacteria that cause common infections 
and that resist treatment with existing antimicrobial medicines [4, 5]. The classical paradigm 
suggests that antibiotic resistance emerges by selection of preexisting mutants in the bacterial 
population exposed to antibiotics [1]. In contrast, recent data suggested that mutations evolve 
after cells encounter antibiotic therapy. This kind of mutation is known as adaptive mutation, 
which is activated by the SOS DNA repair and mutagenesis pathways [6, 7].
 The SOS system is the bacterial DNA damage response that is activated by DNA damage or 
stalled DNA replication caused by the exposure of bacteria to stressful conditions [8] such as 
antibiotic treatment [9], starvation [10], and oxidative stress [11]. Repair of damaged DNA is 
critical for bacterial survival, and during this process, some mutations may be introduced into 
the genome, which may result in bacterial drug resistance [12, 13]. Accumulation of single-
stranded DNA (ss-DNA) is the signal that induces the SOS response by promoting the for-
mation of the RecA filament, which in turn activates the auto-cleavage activity of LexA and 
allows expression of several genes [8]. The SOS response is a very orchestrated pathway by 
which the bacterial cell improves its capacity to inhibit cell division, repair DNA, and express 
error-prone DNA polymerases to replicate noninstructive DNA lesions [14]. This pathway 
has been widely studied in Escherichia coli where more than 40 genes are involved [15]. The 
first stage of SOS response is the expression of genes related to nucleotide excision repair 
mechanisms (uvrA, uvrB, uvrD, polB, ruvA, ruvB, and dinI). If the damaged is not repaired 
the genes responsible for recombination repair mechanisms (recA and recN) are expressed. 
Finally, if the SOS response is not successful, then the sulA and umuDC genes are expressed. 
SulA inhibits cell division and the umuDC operon encodes the error-prone DNA polV crucial 
in translesion error-prone DNA synthesis. When sulA is expressed in the late stage of the 
SOS gene expression, it arrests cell division by binding FtsZ and provides extra time for the 
mutagenic error-prone polymerases to acquire mutations that allow cells to escape from the 
metabolic and genomic stress [8, 16–18]. 
Some difference may be found in the SOS response for each species. For example, this process 
in Bacillus subtilis is mediated by a similar number of genes than in E. coli, however, only 
seven genes are common for these two bacteria [19]. In the case of Staphylococcus aureus, only 
sixteen genes have been identified under the control of LexA, between them one error-prone 
polymerase is designated here as umuC (SACOL1400) [9, 20]. The SOS pathway plays a critical 
role in several processes related to pathogenesis of S. aureus, such as emergence of antibiotic 
resistant strains [21], dissemination of virulence factors [22], and increase of the frequency of 
small colony variants (SCVs) [23]. In this sense, this chapter aims to provide a comprehensive 
review about the modulatory effects of compounds (natural or synthetics) on SOS response 
of S. aureus.
The Rise of Virulence and Antibiotic Resistance in Staphylococcus aureus96
2. Overview of SOS response in Staphylococcus aureus
Since DNA damage may occur as a result of environmental agents and drugs, the role of SOS 
pathway in different conditions has been studied in S. aureus [21–23]. Most of these studies 
have focused on the effects of clinical relevant antibiotics, especially those from fluoroqui-
nolone class, such as ciprofloxacin. The induction of SOS response in this pathogen has been 
associated with mutagenesis, spread of virulence factors, and formation of small colony vari-
ants [22–27]. We discuss some of the papers related to these subjects in the following topics.
2.1. SOS response affects the expression of virulence factors in Staphylococcus aureus
To prove this concept, the effects of SOS response in the dissemination of pathogenicity 
island-encoded virulence factors in staphylococci was evaluated [22]. S. aureus pathogenicity 
island (SaPI) comprises a large family of highly mobile phage-related chromosomal islands, 
which carry a range of virulence genes, for example, TSST1 (toxic shock syndrome toxin), 
SEB (staphylococcal enterotoxin B), and other superantigens [28]. SaPI are widely distributed 
among Gram-positive bacteria and they are considered as prototypes for the understand-
ing of the mobile mechanisms of pathogenicity islands, since horizontal gene transfer has an 
extremely important role in bacterial evolution [29]. It was demonstrated that SOS induction 
(by ciprofloxacin) induced SaPI excision and replication with participation of at least three 
different temperate phages (80, 11, and 147). SOS pathway also regulates the replication and 
high-frequency transfer of this element, as well as of SaPI1. Theses finds suggested that SOS 
activation by antibiotics may lead to the spread of staphylococcal virulence genes, an unin-
tended consequence [22]. 
The influence of subinhibitory concentrations (Sub-MIC) of others antibiotics in the induc-
tion of SOS response and horizontal transfer of virulence factors in S. aureus was also 
evaluated [24]. The authors used antibiotics with different action mechanisms such as lac-
tams (ampicillin, penicillin, ceftriaxone, and cloxacillin), macrolide-β lincosamide-strepto-
gramin B antibiotics (erythromycin), aminoglycosides (kanamycin), chloramphenicol, and 
tetracycline. From these drugs, only β-lactams induced replication of SOS- inducible pro-
phages 80α and 11φ, resulting in SaPIbov1 transfer. The effects of ciprofloxacin and trim-
ethoprim (a folic acid inhibitor from sulfonamide class) on phage induction and expression 
of phage-encoded virulence factors were evaluated using S. aureus strains isolates from 
patients with cystic fibrosis [25]. This study analyzed the integration of phages into the 
chromosomal gene coding for β-hemolysin (hlb), these phages encode for accessory viru-
lence determinants such as staphylokinase (sak; a plasminogen activator essential for bac-
teria dissemination from clots and abscesses and resistance against human defensins) and 
enterotoxins [30, 31]. Sub-MIC of both drugs resulted in delysogenization of strains and 
replication of hlb-converting phages in a dose-dependent manner. The involvement of SOS 
response in phage mobilization was demonstrated by increase of recA expression. In addi-
tion, induction of 13 was directly associated with phage-encoded virulence gene sak [25]. 
In another study, the expression of type 5 capsular polysaccharide (CP5) in S. aureus was shown 
to be linked to SOS response [32]. CP5 is one virulence factor that is important for protection 
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against phagocytes [33] and it is an attractive candidate for the development of immunothera-
pies [34]. The production of CP5 is influenced by various environmental agents (carbon diox-
ide, iron concentration, and specific nutrients) and controlled by a complex regulatory genetic 
network [35]. Using a transposon-mediated mutagenesis assay, seven genes were identified 
affecting the production of CP5, including sbcD and sbcC genes [35]. These genes are adjacent 
forming the sbcDC locus that negatively affects capsule production. Sub-MIC of SOS inducers 
(ciprofloxacin or mitomycin C) promoted the transcription of sbcDC locus and consequently 
repressed the CP5 production [32]. The authors suggested that this effect of SOS response in 
capsule expression could be related to (i) energy saving (the energy needed to capsule biosyn-
thesis would be used for DNA reparation); (ii) improvement of adhesion capability (capsule 
absence would unmask the adhesion proteins present in cell membrane, promoting bacterial 
infection and thereby avoiding DNA-damaging agents). These results corroborate with pre-
vious study which showed that ciprofloxacin increased the expression of fibronectin-binding 
proteins (FnBPs) in fluoroquinolone-resistant S. aureus strains [36].
2.2. SOS response and mutagenesis in Staphylococcus aureus
Apart from its capacity to express virulence factors, S. aureus is extremely able to acquire 
resistance to virtually any antibiotic. For example, methicillin-resistant S. aureus (MRSA) 
strains are important etiologic agents of both nosocomial and community infections. It 
has been shown that Sub-MIC of fluoroquinolone drugs enhances methicillin resistance in 
community or nosocomial MRSA isolates [26, 37]. Community-associated MRSA isolates 
(CA-MRSA) grown in tryptic soy broth containing sub-MIC of fluoroquinolone (ciprofloxa-
cin or levofloxacin) showed increased resistance in nafcillin agar, and this effect was dose-
dependent. Through microarray analysis it was possible to conclude that alterations-induced 
fluoroquinolone drugs were mediated by SOS response [26]. In the same context, a later study 
evaluated the effects of Sub-MIC of ciprofloxacin in the development of rifampin resistance 
in methicillin-susceptible S. aureus (MSSA) and MRSA strains. Ciprofloxacin induced higher 
frequencies of rifampin-resistant mutants. A significant proportion of these mutants exhibited 
in-frame deletions or insertions in the rpoB gene at several positions, while those mutants 
from ciprofloxacin-free cultures essentially showed single-amino-acid substitutions [27].
2.3. Induction of SOS increases the frequency of small colony variants in Staphylococcus 
aureus
Recently, the activation of SOS response was linked with the enhanced incidence of small 
colony variants (SCVs) in S. aureus [11, 23]. S. aureus SCVs are marked by small colony with 
slow growth phenotype, which is associated with intracellular persistence and reduced anti-
microbial susceptibility [38]. S. aureus switch to SCVs phenotype under the pressure of stress 
elicitors such as oxidative stress [11], cold stress [39], and drug treatment [23]. SCVs are fre-
quently associated with latent or chronic infections, including device-associated infections, 
bone and tissue infections, and airway infections of cystic fibrosis patients [40].
S. aureus SCVs present mutations in one or few genes related to metabolic pathways result-
ing in atypical biochemical characteristics [41]. The nature of these mutations is directly 
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related to the antibiotic resistance profile exhibited by the SCVs. Resistance to trimethoprim- 
sulfamethoxazole has been associated to alteration on thyA gene, which encodes thymidylate 
synthase [42, 43]. This enzyme is essential for DNA biosynthesis as it converts deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Diminished concentra-
tions of intracellular dTMP lead to thymidine-dependent SCVs phenotypes (TD-SCVs), which 
is associated to trimethoprim-sulfamethoxazole resistance and hypermutability [44, 45].
On the other hand, mutations in genes related to menadione or hemin synthesis result in 
electron transport-defective strains as bacteria are unable to produce menaquinone and cyto-
chromes, respectively [46, 47]. SCVs auxotrophic for menadione or hemin are resistance to 
aminoglycosides (such as gentamicin) due to a decrease in drug uptake [48]. Fluoroquinolones 
and mitomycin C Sub-MIC increased the generation of gentamicin-resistant SCVs with an 
increased mutation rate through activation of the SOS response [23]. The SOS response is also 
essential for the adaptation of S. aureus to oxidative stress, in this case by producing hydrogen 
peroxide–resistant SCVs [11].
3. New compounds able to modulate the SOS response in Staphylococcus 
aureus
Given the role of SOS response in S. aureus survival and pathogenesis, the effects of new anti-
microbial candidates on SOS genes have become more frequently evaluated, especially those 
which target DNA structure or DNA replication machinery [49, 50]. Gottschalk et al. [49] 
reported an easy and inexpensive agar-based assay to detect the expression of recA induced 
by a compound. In this assay, a S. aureus 8325-4 derivative strain carrying the recA gene fused 
with the reporter gene lacZ (which encodes for β-galactosidase) is incorporated in agar plates 
containing X-Gal (5-bromo-4-β chloro-3-indolyl-D-galactopyranoside). X-gal is a chromo-
genic substrate for β-galactosidase that produces a rich blue color that can easily be detected 
visually. The compound to be tested should be added in wells in these agar plates and the 
expression of recA is monitored as a blue ring at the point of bacterial growth. Using this 
assay, the ability of some compound to active SOS response was revealed, such as the lysine-
peptoid hybrid LP5 [49], some cyclic peptide inhibitors of the β-sliding clamp [50], and the 
amphibian peptide fallaxin analogue FL9 [51]. The induction of SOS response was also related 
to the anti–S. aureus action of new synthetic bis-indole antibiotics [52]. All these compounds 
inhibit the DNA replication of S. aureus.
Special attention has been given to the use of SOS inhibitors as therapeutic adjuvants in com-
bating bacterial infections. These approaches involve inhibiting the SOS-mediated mutagen-
esis induced by drugs and thus improving their long-term viability. In these cases, LexA 
and RecA represent potential targets [53, 54]. In fact, the number of SOS inhibitors is still 
limited and most of the studies use E. coli as model [55, 56]. Regarding the suppression of 
SOS response in S. aureus, a study showed baicalein as a potential compound. Baicalein is 
the main component of the Chinese herb Scutellaria baicalensis Georgi (Labiatae), which 
shows anti–S. aureus and antioxidant activities [57, 58]. Baicalein inhibited the expression 
of some SOS genes (recA, lexA, and LexA-regulated DNA polymerase SACOL1400) and the 
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 rifampin-resistant  mutation ratio induced by Sub-MIC of ciprofloxacin. The authors corre-
lated these effects in SOS response with a decrease in the formation of intracellular reactive 
oxygen species and ATP level after baicalein treatment [59].
In a later study, the effects of novobiocin in the SOS response induced by ciprofloxacin were 
evaluated. Novobiocin is an aminocoumarin, a class of antibiotics that interferes with ATPase 
activity of the gyrase subunit B and the topoisomerase IV subunit ParE without inducing 
double-strand breaks [60–62]. Differently from quinolones, aminocoumarin treatment does 
not activate SOS response. In fact, novobiocin inhibited the recA expression in a LexA-
independent manner. Novobiocin was also able to suppress the SOS response induced by cip-
rofloxacin: it inhibited recA expression and partially reduced the induction of the error-prone 
polymerase umuC (regulated by LexA). These effects resulted in a reduction in the frequency 
of recombination, mutation, and the formation of nonhemolytic variants [20].
The concept that SOS response is a potential target was additionally explored using antimicro-
bial photoinactivation. Antimicrobial photodynamic therapy (aPDT) is a promising strategy 
for the treatment of localized infections, such as acne inflammation [63], periodontal, and peri-
implant diseases [64]. aPDT consists in the use of three elements (photosensitizer agent, visible 
light, and oxygen), where the damage of different bacterial structures (cell envelopes, lipids, 
proteins, and DNA) would avoid the development of resistance [65]. The role of DNA dam-
age and SOS response during photoinactivation was recently established. Different exogenous 
photosensitizers induced DNA damage and consequently the expression of recA. The repres-
sion of recA by novobiocin or gene deletion resulted in additional susceptibility of S. aureus 
toward photoinactivation through increase of DNA damage. These results suggested that the 
combination of recA inhibitors and photoinactivation could have a clinical relevance [66].
SOS response in E. coli has been shown to be regulated by ribonuclease E (RNase E), an 
enzyme involved in RNA metabolism (global mRNA degradation, maturation of rRNA, and 
small regulatory RNA) [67]. RNase E deficient strains exhibit a reduction in SOS activation, 
revealing that RNase E inhibitors could be possibly used as drug adjuvants [68]. Although 
RNase E orthologs have been identified in a range of other bacteria and in bacteria and chloro-
plasts [69, 70], RNA turnover is not regulated by an RNase E ortholog protein in S. aureus [70]. 
Instead, S. aureus has an mRNA degradosome complex formed by diverse proteins, including 
RNase enzymes (RNase J1, RNase J2, RNase Y, and RnpA), enolase, phosphofructokinase, 
polynucleotide phosphorylase (PNPase), and DEAD box RNA helicase. RnpA, a component 
of this complex, has been reported as a target to inhibit bacterial survival and pathogene-
sis [70, 71]. However, the role of mRNA degradosome complex in SOS response regulation 
remains to be elucidated in this pathogen.
4. Conclusion
The SOS response is an essential pathway for S. aureus survival and pathogenesis. This 
mechanism is activated by different stress situations (such as environmental alteration, drug, 
and toxins treatment), which lead to mutagenesis, phenotypical alterations, and spread of 
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 virulence factors. All these consequences of SOS activation are important to pathogen dissem-
ination and treatment failure. SOS proteins are potential target for therapies, especially those 
using quinolones and RecA/LexA inhibitors. These studies have shown that SOS inhibitors 
are able to decrease drug-induced mutagenesis in S. aureus. We hope that more researches 
will be performed in the future to identify more compounds that are able to modulate SOS 
response, as well as deeper in vivo studies to establish the clinical relevance of them.
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